SCHEMBL24904290

SCHEMBL24904290

Cn1c(CC(C)(C)c2ccc3ncccc3c2)nc2ccc(C(C)(C)C)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
ALDH1A1 P00352 3/20 0.38
TP53 P04637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MET P08581 4/20 0.37
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
ESRRA P11474 1/20 0.36
GAA P10253 1/20 0.35
PDE10A Q9Y233 2/20 0.35
PDE2A O00408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264293 0.78 ALDH1A1 (0.58) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL22617566 0.75 ALDH1A1 (0.40) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL20932780 0.74 ALDH1A1 (0.39) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL26315520 0.74 ALDH1A1 (0.39) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL19750751 0.73 MAPT (0.38) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL10285521 0.72 ALDH1A1 (0.51) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL21497380 0.72 GNRHR (0.41) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL24989426 0.70 SSTR4 (0.34) MAPTTP53
SCHEMBL26033494 0.69 ALDH1A1 (0.47) MAPTALDH1A1TP53KDM4ESMN1; SMN2
SCHEMBL25992706 0.69 NPC1 (0.41) MAPTALDH1A1TP53KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 MAPT 4785/4885ALDH1A1 1360/4885TP53 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.